Human Genome Sciences Dodges Mortality Boxed Warning, REMS For Benlysta

Human Genome Sciences escaped a boxed label warning and a Risk Evaluation and Mitigation Strategy for its lupus drug Benlysta (belimumab), despite FDA expectations late in the review process that both would be needed.